Quality/GMPs

At some point, will heavy investments in large, stainless-steel based facilities become a burden to US companies?

Broader transparency in product prices and payments to researchers aim to curb conflicts of interest and rationalize drug expenditures.

With counterfeit and adulterated medicines posing an increasing risk to patients in the United States and worldwide, the US Pharmacopeial (USP, Rockville, MD) Convention announced on February 4, new standards for two widely used drug products that have been involved in episodes of adulteration resulting in patient deaths.

How change plays out will depend not only on the new Whitehouse, but on pharma leaders' ability to adapt to changing times.

QbD for QA? Try a two-step approach

Choosing the right tools to enhance the process.

With cuts in healthcare, biotech drugs are under scrutiny.

Understanding the relationship between the process and CQAs.

FDA aims to regain public confidence in 2009.

Optimize time and cost of product development by managing risk.

Looking ahead at the biopharmaceutical industry into 2009.

QbD can help satisfy FDA and EMEA requirements.

The development of a skilled labor force is essential for an expanding biopharmaceutical industry.

To expand coverage amidst the economic crisis, Obama will be looking hard for ways to cut healthcare costs.

To stave off quality issues associated with production processes, a centralized and enterprise-wide quality management initiative must be enforced.

A clear oversight framework for biomarker clinical laboratory tests used in personalized medicine is required.

No time for QbD? How to convince management to make it a priority.

The FDA's revised process validation guidance manages to explain the underlying concepts of Quality by Design without every using the phrase.

Using multivariate experiments to define acceptable ranges.

Translate the concepts in to practical applications and reduce waste.

FDA perspectives on specs and effective control strategies.

The FDA and other regulatory authorities are evaluating new regulations to ensure the safety and quality of nanomaterials in biomedical products.

Well-designed experiments can reduce the risk of coming to an incorrect conclusion during a process characterization, assay validation, or process validation study.

Supplemental tables for the above-mentioned article, providing additional information about the application of operational excellence methods.

A centralized quality control strategy may be the best solution.